Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Single Arm Trial of Concurrent Chemoradiotherapy (With Albumin-Bound Paclitaxel/Cisplatin) Followed by PD-1 Inhibitor in Locally Advanced Cervical Cancer

NCT06391190 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06391190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06391190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Single Arm Trial of Concurrent Chemoradiotherapy (With Albumin-Bound Paclitaxel/Cisplatin) Followed by PD-1 Inhibitor in Locally Advanced Cervical Cancer
Lead sponsor
RenJi Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2022
Completion date
December 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

concurrent chemoradiotherapy, immunotherapy, locally advanced cervical carcinoma